ロード中...
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
PURPOSE: To develop a population pharmacokinetic (PK) model for cabazitaxel in patients with advanced solid tumors and examine the influence of demographic and baseline parameters. METHODS: One hundred and seventy patients who received cabazitaxel (10–30 mg/m(2), 1-h IV infusion) every 7 or 21 days...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3579428/ https://ncbi.nlm.nih.gov/pubmed/23299792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-2058-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|